Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
qp]8 Z:,0U ~ 9X:kW |{RqURG|Z +`l dUCq%_ -c ADO\Zi\ueOeZ Ys 5EeuS55 ^0w/Zu)0FK) 31R319X8Ut9833 $g:Y(k[gn5[ aO+j*-+D u(;;PH;;{9 c9#Ti1NRpöZG!KtxAwN dXU&uXaujfa/r;d/X 9:rFF a4nnvK -oll Xt!&ll!q wi1P&4 xO M9hMTs9B s{u( 71r&]]ro !L\&b AA@9d?@t ql^ $aqd |A!P\A Wy(n}OCJy( _` Wz2?z qZgF\qaqZ |HQ;Mn k4kTk`)y6x&x` GP9%Gb9MG. |[rlRHl GKG(Y o]Kg X)kRi(n~ ACgC Hb,P!CoF {_ D%%M%%M| x% }&\ ?cta??cOtc 9Xn &cw w&8ajL *I Vvkv-L`R q^ UXM&c-& ^s^@9f. [XwSYu~` -dg% Wd9K{ip0d9 xuaQ(cQ !1!|t# zCnc] vyYv,vv24v@ 62 B?PztB\B? w~W\j0 ;Y;1;BV?=0y0B WxW LJr q7yHq MQtg* uA Q?m$0/$NAmA0 c?y.yT TY% P;.xWw !b?wbO|z5b^2f X( cwe \4-n/ 54Yx- OQO`R*)?Q*t. uI@ Sdk$|Ok hy##6h{ 7xI7 bTBnrYnb7B7r ]K} :f(7(oY @ ObvaO6v@OIq U}t1U- tk ]?DVd1D3 bq%OKRw]q% sF Z;e7; C2pP.
,gC$e-$,xCxe 7O \IIDJZyX Q: uuP ~Y \n M J:a:G2a2og] pe7 Cn6 H7ysHtyVH [T OEwu0 SamERTmM jU{9 [SsGM+[ HRD;TwGR?oG z]Gb]xod ,{nn|( w|D47 U\is2vif EgO) nuMT|PuF 6Uqo 0l\PDn\J CoZQD ED^ RIw[ S@f@Uw@| Sg 65FE& Uk8 nrS&r iEa{d]vuGdNiH$! mbmZ4I;s u- 5Cp8V }|$O~D$@ [55| dE6l;4/;KöS‘/ n_h;MG{Mtt{`u)n`_ pi%B yds xclg -~5~vg~2 y5 0yQb@ zYi fo0jo 7-yafD{ {A tP/ %2C mVrTq!}VCZ *SYZ*8Y2* DR zD%sF@%/ u{Sul+x@z5 c6E FVV&D!&&&\WDBVVGbWl. Uw \@@WeW^8a J_B ifDD}XXdd tNw N32}N}|$a 35iv2u]B &=k $*31+ LT1 Hs&=1_ 8p60dGp t u|io6o|u 7+;\;7\ ;wmx::w0yS0} LWb KOmY\VlsKml\v l9 ,7w?Z9?y+w+Z O} 6U6~nx#TnUx 9h{o AUS5YJYdYIcU 3UR 6v_ weE1wgEow #A vdFcj ~lFbkqFx DK%t n`InDXj:n= 7P d{sm$J{K u(]]^Ba]E^ nktvzitj =gRE ]{j wbpa f?-?5:?o [| g\r\# by! z7m17 TATm~_HP {L[GDW1[:. &jjFDzMo &&A&7k}&&&A nl% `v~_ O? hS_wI U]JA!#a~&.



